Issue 3/2021
Content (12 Articles)
CD37 and CD44 evaluation by flow cytometry: can these markers improve B cell lymphoma characterization?
Joanna Chaffin, Sayedamin Mostofizadeh, Robert Seifert
Multiple myeloma and frequency of synchronous and second primary malignancies
Atakan Turgutkaya, İrfan Yavaşoğlu, Tuğba Şahin, Gökhan Sargın, Ali Zahit Bolaman
The impact of CD33/CD34 ratio in the prognosis of myelodysplastic syndrome treated with azacitidine for first-line therapy
Satoko Oka, Kazuo Ono
Polymerase chain reaction-restriction fragment length polymorphism method for detection of Calreticulin type-1 and type-2 mutations in myeloproliferative neoplasm
Shano Naseem, Jogeshwar Binota, Neelam Varma, Priti Satyarthi, Palak Rana, Pankaj Malhotra
Blood cell morphology and COVID-19 clinical course, severity, and outcome
Amirhossein Pezeshki, Atefeh Vaezi, Pardis Nematollahi
Hemophagocytic lymphohistiocytosis, a new cause of death during ‘post-acute COVID-19 syndrome?’ A case report
Elie Naous, Bertha-Maria Nassani, Cesar Yaghi, Fadi Nasr, Rita Medlej
Extracutaneous involvement of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis and refractory to intensive chemotherapy
S. H. T. Peng, B. Wong, W. Chen, R. Lai, L. A. Canterbury
Primary thyroid T cell lymphoproliferative disorder with a 10-year history of neck mass: a case report and literature review
Kyung Han Nam, Bomi Kim
Sequential development of JAK2V617F and BCR-ABL1: a “double-hit” myeloproliferative neoplasm with morphologic transition
Yue Zhao, Jenna McCracken, Endi Wang
Coexistence of pseudo-Pelger-Hüet anomaly and faggot cells in acute promyelocytic leukemia during chemotherapy
Ting Li, Dongyan Li, Xueyan Chen
Medication-induced Pseudo-Pelger-Huët Anomaly and severe neutropenia
Krasimira A. Rozenova, Min Shi